Global, regional, and national burden of Hodgkin lymphoma, 1990-2021, and predictions for 2050: an analysis of the global burden of disease study 2021.
{"title":"Global, regional, and national burden of Hodgkin lymphoma, 1990-2021, and predictions for 2050: an analysis of the global burden of disease study 2021.","authors":"Dongnan Li, Yunjie Li, Yue Chen, Qiuni Chen, Jingjing Ma, Chuanyang Lu, Yuye Shi, Chunling Wang, Liang Yu","doi":"10.1080/17474086.2025.2558710","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hodgkin lymphoma (HL), a lymphoid malignancy with bimodal age incidence, was analyzed across 204 countries (1990-2021) using data from the global burden of disease (GBD) 2021, with projections till 2050.</p><p><strong>Research design and methods: </strong>Using GBD 2021 data, we assessed HL burden via incidence, mortality, and disability-adjusted life years (DALYs), with age-standardized rates/100,000. Trends were evaluated using frontier analysis, age-period-cohort modeling and Bayesian APC methods.</p><p><strong>Results: </strong>From 1990-2021, global HL cases increased 19.2%, while age-standardized incidence rate (ASIR) fell 29.5%. Mortality declined 46.0%, with males showing higher ASIR (0.95 vs. 0.64) and mortality rates (0.43 vs. 0.26). High Socio-demographic Index (SDI) regions had the highest ASIR (1.42) but fastest mortality declines (estimated annual percentage change(EAPC): -3.38), whereas low SDI areas exhibited the highest age-standardized mortality rate (ASMR: 0.7) and minimal improvement. Eastern Sub-Saharan Africa recorded peak ASMR (0.85) and DALY rates (ASDR: 36.96). Bayesian Age-Period-Cohort(BAPC) projections predict sustained ASIR, ASMR, and ASDR reductions until 2050, with persistent gender/age disparities.</p><p><strong>Conclusions: </strong>Despite rising HL cases due to demographic changes, age-standardized incidence, mortality, and DALYs declined substantially over three decades and are projected to continue declining through 2050, indicating improved treatments. Persistent disparities across SDI tiers underscore the need for region-tailored strategies.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-10"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2558710","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hodgkin lymphoma (HL), a lymphoid malignancy with bimodal age incidence, was analyzed across 204 countries (1990-2021) using data from the global burden of disease (GBD) 2021, with projections till 2050.
Research design and methods: Using GBD 2021 data, we assessed HL burden via incidence, mortality, and disability-adjusted life years (DALYs), with age-standardized rates/100,000. Trends were evaluated using frontier analysis, age-period-cohort modeling and Bayesian APC methods.
Results: From 1990-2021, global HL cases increased 19.2%, while age-standardized incidence rate (ASIR) fell 29.5%. Mortality declined 46.0%, with males showing higher ASIR (0.95 vs. 0.64) and mortality rates (0.43 vs. 0.26). High Socio-demographic Index (SDI) regions had the highest ASIR (1.42) but fastest mortality declines (estimated annual percentage change(EAPC): -3.38), whereas low SDI areas exhibited the highest age-standardized mortality rate (ASMR: 0.7) and minimal improvement. Eastern Sub-Saharan Africa recorded peak ASMR (0.85) and DALY rates (ASDR: 36.96). Bayesian Age-Period-Cohort(BAPC) projections predict sustained ASIR, ASMR, and ASDR reductions until 2050, with persistent gender/age disparities.
Conclusions: Despite rising HL cases due to demographic changes, age-standardized incidence, mortality, and DALYs declined substantially over three decades and are projected to continue declining through 2050, indicating improved treatments. Persistent disparities across SDI tiers underscore the need for region-tailored strategies.
期刊介绍：
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
